For research use only. Not for use in humans.

Anti-GPRC5D

Synonyms: GPRC5D, RAIG4

Anti-GPRC5D is a specific antibody against G protein-coupled receptor C5 family member D (GPRC5D).

Anti-GPRC5D

Quality Control

Batch: Purity: 99% Protein concentration: 5.63mg/ml Endotoxin Level: <1EU/mg
99

Specificity

Name Citation GPR Others
AZD1981 1
NF-56-EJ40 0
ML401 0
PH-064 0
NE 52-QQ57 2 IL-1β,TNF-α,PGE2
NIBR189 0
JMS-17-2 2
OC000459 0
Kisspeptin-10 (human) 0
CLP-3094 0 AR
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Anti-GPRC5D is a specific antibody against G protein-coupled receptor C5 family member D (GPRC5D).

Product Details

CAS No. 2226212-40-2
Molecular Weight 145.5 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07474961 NOT_YET_RECRUITING Drug: teclistamab OR talquetamab OR elranatamab OR linvoselt Waldenstrom Macroglobulinaemia; Multiple Myeloma Anne Louise Tølbøll Sørensen 2027-03 PHASE4
NCT07455851 RECRUITING Drug: Linvoseltamab|Drug: REGN17372+Linvoseltamab Relapsed Refractory Multiple Myeloma (RRMM) Regeneron Pharmaceuticals 2026-03-26 PHASE1; PHASE2
NCT07649525 RECRUITING Drug: Daratumumab|Drug: Lenalidomide|Drug: Dexamethasone|Dru Multiple Myeloma (MM); Plasma Cell Leukemia (PCL) University of Leeds 2026-07 PHASE3
NCT07740486 NOT_YET_RECRUITING Drug: Teclistamab|Drug: Talquetamab|Drug: Daratumumab (Subcu Multiple Myeloma (MM) Polish Myeloma Consortium 2026-09 PHASE3
NCT06630806 RECRUITING Drug: SAR446523 Plasma Cell Myeloma Refractory Sanofi 2024-10-30 PHASE1
NCT05552222 RECRUITING Drug: Teclistamab|Drug: Daratumumab|Drug: Lenalidomide|Drug: Multiple Myeloma Janssen Research & Development, LLC 2022-10-25 PHASE3

(data from https://clinicaltrials.gov, updated on 2026-03-16)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.